FTC Orders Greater HSR Reporting of Patent Licenses in the Pharmaceutical Sector

by Dechert LLP

Background. One item on the negotiation checklist for patent licenses in the pharmaceutical sector is compliance with the U.S. Hart-Scott-Rodino (“HSR”) Premerger Notification Rules. The HSR rules require that certain patent licenses be reported to the Federal Trade Commission (“FTC”) before implementation. Up until now, the majority of such licenses were not subject to reporting requirements. Changes made by the FTC, taking effect in December, will require greater reporting of pharmaceutical patent licenses.

The changes made by the FTC expand the types of pharmaceutical patent licenses subject to early antitrust scrutiny and will impose additional costs (including in time and filing fees) on companies engaging in these transactions. Failure to report these transactions may result in civil penalties. Here is what business development and law department managers in the pharmaceutical industry need to know about the new rules.

The most significant change concerns patent licenses in which the licensor retains substantial rights (for example, the right to manufacture). These licenses may be reportable under HSR, regardless of whether the parties label them as “exclusive.” Under the amendment, the test will be whether the license transfers to the licensee “all commercially significant rights” in a patent.

What Stays the Same: Patents Are Assets and Licenses Can Be Subject to Premerger Notification

  1. Patents Are Assets for HSR Purposes. The HSR Act requires reporting of large acquisitions of voting securities and assets. The amendment does not change the well-established principle that patents are assets for HSR purposes. As a form of property, a patent is an asset and thus the acquisition or assignment of a patent from another party is subject to the HSR Act.
  2. Exclusive Patent Licenses Are Acquisitions of Assets for HSR Purposes. The amendment also does not change the principle that a traditional exclusive license is an asset acquisition for HSR purposes. The FTC views an exclusive license the same as a patent acquisition or assignment and thus insists on pre-closing reporting and antitrust review of covered exclusive patent licenses. This principle applies to exclusive patent licenses even if they are limited in scope, for example to specific indications or therapeutic areas.
  3. Other HSR Tests Remain the Same. The amendment also does not change the size-of-the-transaction test, the size-of-the-parties test, and the exemptions used to determine when an exclusive patent license must be reported. Early stage licenses are likely to continue to be exempt from reporting under these tests.

The Key Change Is that Patent Licenses with “Co-Rights” Are Now Clearly Subject to HSR Reporting

The FTC initiated the rule-making based on its observation that pharmaceutical patent licensors often retain some rights. The licensor may retain the right to manufacture for the licensee, or the rights to co-develop, co-promote, or co-market. Questions arose over how to treat these types of patent licenses for HSR purposes.

The new rule establishes that the retention of co-rights does not render a license non-exclusive and, therefore, outside of the scope of the HSR reporting requirements. The FTC introduced, but did not clearly explain, a new “all commercially significant rights” test as the standard. Under this new test, if the licensee receives “all commercially significant rights” to the patent, the license is subject to HSR, regardless of whether it is labeled as an “exclusive” license by the parties.

The illustrations below, which correspond in part to several illustrations provided by the FTC, explain the application of the new FTC rule. These illustrations assume that all other elements of the HSR test, such as the size-of-the-transaction and size-of-the-parties tests, are met, and that no HSR exemptions apply.

  • Illustration 1. The patent license grants the right to use the patented technology and sell the patented product to the exclusion of all others, except that the licensor will perform all manufacturing for the licensee. This will be reportable as a transaction transferring all commercially significant rights.
  • Illustration 2. The same facts as Illustration 1 except that the license is limited to a particular therapeutic area or indication. This will be reportable as a transaction transferring all commercially significant rights.
  • Illustration 3. The patent license grants the right to make, use, and sell the patented product to the exclusion of all others except that the licensor retains rights to promote and market. The licensee will book the sales and the licensor will benefit from sharing in greater royalties or other revenue sharing. This will be reportable as a transaction transferring all commercially significant rights.
  • Illustration 4. The patent license grants the right to make, use, and sell the patented product except that the licensor retains rights to manufacture and sell. The licensor will book the sales and retain revenues from its sales. The licensee has not obtained all commercially significant rights.

Early Antitrust Assessment Is More Important Than Ever. The amendment increases the need to include an antitrust review early on in the negotiation process for a pharmaceutical license agreement. A screening should be performed to identify potential substantive antitrust risks arising from licensing transactions, such as consolidation or entrenchment of the licensee’s leadership position in a relevant market, which could be limited to a particular therapy or indication. As a result of this rule change, more licenses will be subject to FTC review prior to closing, and it will be more important than ever to assess the potential competitive effects of the license, particularly where the parties are actual or potential competitors.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Dechert LLP | Attorney Advertising

Written by:

Dechert LLP

Dechert LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.